Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194444 | 0.89 | EPHX2 (0.34) | EPHX2USP2SMN1; SMN2TSHRALOX15 | |
| SCHEMBL391708 | 0.86 | USP2 (0.45) | EPHX2USP2SMN1; SMN2TSHRALOX15 | |
| SCHEMBL1003478 | 0.82 | EPHX2 (0.34) | EPHX2USP2SMN1; SMN2TSHRALOX15 | |
| SCHEMBL28049727 | 0.81 | DRD2 (0.34) | EPHX2MEN1KMT2A | |
| SCHEMBL21777669 | 0.79 | EPHX2 (0.40) | EPHX2USP2SMN1; SMN2TSHRALOX15 | |
| SCHEMBL28189059 | 0.77 | CYP4F2 (0.33) | EPHX2USP2SMN1; SMN2TSHRALOX15 | |
| SCHEMBL142219 | 0.77 | MEN1 (0.39) | MEN1KMT2A | |
| SCHEMBL7009183 | 0.75 | EPHX2 (0.40) | EPHX2USP2SMN1; SMN2TSHRALOX15 | |
| SCHEMBL4463790 | 0.75 | DRD2 (0.33) | EPHX2USP2MEN1KMT2A | |
| SCHEMBL1003450 | 0.74 | USP2 (0.44) | EPHX2USP2SMN1; SMN2TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101623-B2 | Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor | ASTRAZENECA AB (SE) | 2012-01-24 | — | — | US | disclosed |
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163524-A1 | Novel Protein Kinase B Inhibitors - 060 | PRKAR2B, PRKCB, MAP3K20 | EPHX2 3726/4885USP2 3516/4885SMN1; SMN2 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.